Merck & Co Inc at Guggenheim Biopharma's Next Decade Virtual Conference Transcript
Okay. Good morning, everybody. Hopefully, you can -- you hear me okay. Thanks very much for joining us for this 60-minute discussion with Merck's Executive Vice President and President of Merck Research Laboratories, Dr. Dean Li.
I'm Seamus Fernandez, one of the biopharma teams' senior therapeutic analyst here at Guggenheim. I'm really pleased that we've got Dr. Li here to join us as part of our new Guggenheim strategy series, which focuses exclusively on the innovation and strategies that biopharma companies are employing to benefit patients and drive growth for many years to come.
Dr. Li, frankly, I can't wait to discuss Merck's efforts and strategy to continue driving growth in the next decade and beyond. But before we do that, I just want to provide a little background and context for the discussion. As many of you know, Dr. Li serves as Executive Vice President, President of Merck Research Laboratories. He leads companies -- the company's worldwide human vaccines
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
